- Author
- Behrouz Hassannia (UGent) , Peter Vandenabeele (UGent) and Tom Vanden Berghe (UGent)
- Organization
- Abstract
- One of the key challenges in cancer research how to effectively kill cancer cells while leaving the healthy cells intact. Cancer cells often have defects in cell death executioner mechanisms, which is one of the r. An reasons for therapy resistance. To enable growth, cancer cells exhibit an increased iron demand compared with normal, non-cancer cells. This iron dependency can make cancer cells more vulnerable to iron-catalyzed necrosis, referred to as ferroptosis. The identification of FDA-approved drugs as ferroptosis inducers creates high expectations for the potential of ferroptosis to be a new promising way to kill therapy-resistant cancers.
- Keywords
- DEPENDENT CELL-DEATH, BUTHIONINE SULFOXIMINE, TUMOR-SUPPRESSOR, INHIBITS, FERROPTOSIS, GLUTAMATE TOXICITY, THERAPEUTIC TARGET, LIPID-PEROXIDATION, OXIDATIVE STRESS, CYCLE ARREST, GLUTATHIONE
Downloads
-
(...).pdf
- full text
- |
- UGent only
- |
- |
- 3.81 MB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8622888
- MLA
- Hassannia, Behrouz, et al. “Targeting Ferroptosis to Iron out Cancer.” CANCER CELL, vol. 35, no. 6, 2019, pp. 830–49, doi:10.1016/j.ccell.2019.04.002.
- APA
- Hassannia, B., Vandenabeele, P., & Vanden Berghe, T. (2019). Targeting ferroptosis to iron out cancer. CANCER CELL, 35(6), 830–849. https://doi.org/10.1016/j.ccell.2019.04.002
- Chicago author-date
- Hassannia, Behrouz, Peter Vandenabeele, and Tom Vanden Berghe. 2019. “Targeting Ferroptosis to Iron out Cancer.” CANCER CELL 35 (6): 830–49. https://doi.org/10.1016/j.ccell.2019.04.002.
- Chicago author-date (all authors)
- Hassannia, Behrouz, Peter Vandenabeele, and Tom Vanden Berghe. 2019. “Targeting Ferroptosis to Iron out Cancer.” CANCER CELL 35 (6): 830–849. doi:10.1016/j.ccell.2019.04.002.
- Vancouver
- 1.Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to iron out cancer. CANCER CELL. 2019;35(6):830–49.
- IEEE
- [1]B. Hassannia, P. Vandenabeele, and T. Vanden Berghe, “Targeting ferroptosis to iron out cancer,” CANCER CELL, vol. 35, no. 6, pp. 830–849, 2019.
@article{8622888,
abstract = {{One of the key challenges in cancer research how to effectively kill cancer cells while leaving the healthy cells intact. Cancer cells often have defects in cell death executioner mechanisms, which is one of the r. An reasons for therapy resistance. To enable growth, cancer cells exhibit an increased iron demand compared with normal, non-cancer cells. This iron dependency can make cancer cells more vulnerable to iron-catalyzed necrosis, referred to as ferroptosis. The identification of FDA-approved drugs as ferroptosis inducers creates high expectations for the potential of ferroptosis to be a new promising way to kill therapy-resistant cancers.}},
author = {{Hassannia, Behrouz and Vandenabeele, Peter and Vanden Berghe, Tom}},
issn = {{1535-6108}},
journal = {{CANCER CELL}},
keywords = {{DEPENDENT CELL-DEATH,BUTHIONINE SULFOXIMINE,TUMOR-SUPPRESSOR,INHIBITS,FERROPTOSIS,GLUTAMATE TOXICITY,THERAPEUTIC TARGET,LIPID-PEROXIDATION,OXIDATIVE STRESS,CYCLE ARREST,GLUTATHIONE}},
language = {{eng}},
number = {{6}},
pages = {{830--849}},
title = {{Targeting ferroptosis to iron out cancer}},
url = {{http://doi.org/10.1016/j.ccell.2019.04.002}},
volume = {{35}},
year = {{2019}},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: